PRVB

Provention Bio, Inc. [PRVB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PRVB Stock Summary

In the News

10:58 29 Mar 2024 PRVB

The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023

March was a good month for the stock market, with the S&P 500 gaining about 3.5%.

04:56 29 Mar 2024 PRVB

Why Provention Bio Stock Skyrocketed 256% This Week

Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup.

01:44 29 Mar 2024 PRVB

Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi

Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.

08:22 29 Mar 2024 PRVB

This biopharma stock jumped over 250% on Monday: what happened?

Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.

07:15 29 Mar 2024 PRVB

Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners

Markets were mixed on a volatile day on Wall Street. Sanofi offered to buy Provention Bio at a price more than triple where the stock closed Friday.

11:17 29 Mar 2024 PRVB

Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio

Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.

10:15 29 Mar 2024 PRVB

Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal

French drugmaker Sanofi has announced an agreement to acquire US-based biopharmaceutical company Provention Bio Inc (NASDAQ:PRVB), which focuses on autoimmune diseases, for $25 per share in cash, or a total equity value of about $2.9 billion. Provention Bio's stock surged more than 250% in early trading on Monday, while shares of Sanofi slipped 1%.

08:13 29 Mar 2024 PRVB

Why Is Provention Bio (PRVB) Stock Up 263% Today?

Provention Bio (NASDAQ: PRVB ) stock is rocketing higher on Monday following news that Sanofi (NASDAQ: SNY ) is acquiring the company. That deal has Sanofi agreeing to acquire Provention Bio for $25 per share in cash.

07:00 29 Mar 2024 PRVB

Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

RED BANK, N.J. , March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions.

06:43 29 Mar 2024 PRVB

Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)

Sanofi (NASDAQ: SNY) announced it is buying Provention Bio (NASDAQ: PRVB) as part of a $2.9 billion deal. These are the details.

PRVB Financial details

Company Rating
Neutral
Market Cap
2.38B
Income
-112.97M
Revenue
12.9M
Book val./share
1.63
Cash/share
2.21
Dividend
-
Dividend %
-
Employees
174
Optionable
No
Shortable
Yes
Earnings
02 Aug 2023
P/E
-16.52
Forward P/E
-
PEG
14.24
P/S
184.21
P/B
15.32
P/C
11.3
P/FCF
-31.17
Quick Ratio
1.84
Current Ratio
1.93
Debt / Equity
0.2
LT Debt / Equity
0.2
-
-
EPS (TTM)
-1.6
EPS next Y
-
EPS next Q
-
EPS this Y
-16.02%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
1330.29%
EPS Q/Q
32.35%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
81.07%
Inst Trans
1.34%
ROA
-48%
ROE
-103%
ROC
-0.88%
Gross Margin
96%
Oper. Margin
-994%
Profit Margin
-876%
Payout
-
Shs Outstand
95.09M
Shs Float
69.61M
-
-
-
-
Target Price
-
52W Range
3.185-25.0
52W High
-0.08%
52W Low
+732.67%
RSI
-
Rel Volume
3.21
Avg Volume
2.84M
Volume
9.12M
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
2.46037
-
-
Volatility
0%, 0%
Prev Close
0%
Price
24.98
Change
0%

PRVB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.020.17
Net income per share
-1.18-1.04-1.88-1.81-1.52
Operating cash flow per share
-1.01-0.89-1.46-1.51-1.01
Free cash flow per share
-1.01-0.89-1.48-1.53-1.02
Cash per share
2.612.12.321.512.21
Book value per share
2.66-1.94-3.39-4.631.63
Tangible book value per share
2.66-1.94-3.391.750.83
Share holders equity per share
2.66-1.94-3.39-4.631.63
Interest debt per share
000.010.010.33
Market cap
39.72M607.13M888.62M354.63M789.82M
Enterprise value
-18.82M567.97M787.04M277.03M769.69M
P/E ratio
-1.5-14.39-9.01-3.1-6.95
Price to sales ratio
000254.2161.25
POCF ratio
-1.75-16.83-11.64-3.72-10.47
PFCF ratio
-1.75-16.83-11.47-3.68-10.36
P/B Ratio
0.67-7.68-5-1.216.48
PTB ratio
0.67-7.68-5-1.216.48
EV to sales
000198.5959.69
Enterprise value over EBITDA
0.71-12.8-7.9-2.4-6.17
EV to operating cash flow
0.83-15.75-10.31-2.9-10.21
EV to free cash flow
0.83-15.75-10.16-2.88-10.1
Earnings yield
-0.67-0.07-0.11-0.32-0.14
Free cash flow yield
-0.57-0.06-0.09-0.27-0.1
Debt to equity
00000.2
Debt to assets
000.0100.1
Net debt to EBITDA
2.20.881.020.670.16
Current ratio
32.8922.397.564.441.93
Interest coverage
0000-123.59
Income quality
0.860.830.770.830.66
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00033.944.97
Research and developement to revenue
00049.915.88
Intangibles to total assets
00000.25
Capex to operating cash flow
000.010.010.01
Capex to revenue
000-0.69-0.06
Capex to depreciation
00-33.67-2.48-0.65
Stock based compensation to revenue
0008.491.48
Graham number
8.46.7211.9713.747.47
ROIC
-0.450.550.560.39-0.78
Return on tangible assets
-0.430.56-0.77-0.84-0.64
Graham Net
2.532-3.511.110.69
Working capital
59.66M82.16M109.82M78.31M84.26M
Tangible asset value
59.66M-79.06M-177.64M110.73M62.29M
Net current asset value
59.66M82.16M-179.61M76.21M59.64M
Invested capital
00000.2
Average receivables
0000679.5K
Average payables
513.87K1.17M4.67M5.56M5.15M
Average inventory
0000615.5K
Days sales outstanding
000038.47
Days payables outstanding
00004.82K
Days of inventory on hand
0000877.57
Receivables turnover
00009.49
Payables turnover
00000.08
Inventory turnover
00000.42
ROE
-0.440.530.550.39-0.93
Capex per share
00-0.02-0.02-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.010.010.010.14
Net income per share
-0.41-0.35-0.46-0.34-0.45
Operating cash flow per share
-0.37-0.24-0.44-0.29-0.11
Free cash flow per share
-0.37-0.24-0.44-0.29-0.11
Cash per share
1.51.341.312.232.21
Book value per share
1.751.491.221.741.63
Tangible book value per share
1.751.491.221.740.83
Share holders equity per share
1.751.491.221.741.63
Interest debt per share
0.010.010.010.290.33
Market cap
356.17M464.09M258.86M374.04M789.82M
Enterprise value
278.57M389.73M201.5M295.43M769.69M
P/E ratio
-3.45-5.28-2.19-3.32-5.93
Price to sales ratio
496.75800.15347494.7673.04
POCF ratio
-15.18-30.88-9.1-15.61-99.04
PFCF ratio
-15.16-30.88-9.03-15.48-94.61
P/B Ratio
3.224.933.292.586.48
PTB ratio
3.224.933.292.586.48
EV to sales
388.52671.95270.11390.7871.18
Enterprise value over EBITDA
-10.84-13.47-6.79-10.46-20.24
EV to operating cash flow
-11.88-25.93-7.09-12.33-96.51
EV to free cash flow
-11.85-25.93-7.03-12.23-92.2
Earnings yield
-0.07-0.05-0.11-0.08-0.04
Free cash flow yield
-0.07-0.03-0.11-0.06-0.01
Debt to equity
0.010.010.010.160.2
Debt to assets
0000.120.1
Net debt to EBITDA
3.022.571.932.780.53
Current ratio
4.443.393.597.581.93
Interest coverage
0510.19-204.34-114.03-51.37
Income quality
0.910.680.960.840.24
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
15.821.2218.7717.852.25
Research and developement to revenue
21.2729.9222.2221.612.36
Intangibles to total assets
00000.25
Capex to operating cash flow
000.010.010.05
Capex to revenue
-0.060-0.3-0.26-0.03
Capex to depreciation
-0.310-1.66-1.36-0.46
Stock based compensation to revenue
3.615.724.294.360.85
Graham number
43.43.533.654.04
ROIC
-0.23-0.23-0.37-0.17-0.23
Return on tangible assets
-0.19-0.18-0.28-0.15-0.19
Graham Net
1.110.90.911.640.69
Working capital
78.31M64.74M65.15M165.32M84.26M
Tangible asset value
110.73M94.21M78.68M144.77M62.29M
Net current asset value
76.21M63.53M64.63M141.29M59.64M
Invested capital
0.010.010.010.160.2
Average receivables
0000679.5K
Average payables
3.59M5.39M6.45M4.72M5.28M
Average inventory
0000615.5K
Days sales outstanding
000011.31
Days payables outstanding
00001.19K
Days of inventory on hand
0000216.39
Receivables turnover
00007.96
Payables turnover
00000.08
Inventory turnover
00000.42
ROE
-0.23-0.23-0.38-0.19-0.27
Capex per share
00000

PRVB Frequently Asked Questions

What is Provention Bio, Inc. stock symbol ?

Provention Bio, Inc. is a US stock , located in Red bank of Nj and trading under the symbol PRVB

What is Provention Bio, Inc. stock quote today ?

Provention Bio, Inc. stock price is $24.98 today.

Is Provention Bio, Inc. stock public?

Yes, Provention Bio, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap